This commentary addresses the possible reasons for treatment gaps between recommended therapy for patients with CKD, and the realities of current practices, and examines new developments that may bridge the gap.
Nancy L. Reaven, MA
Advertisement
Articles by Nancy L. Reaven, MA
A budget-impact model illustrates the economic outcomes associated with renoprotective therapy on privately insured patients with advanced kidney disease.
Advertisement
Latest Updated Articles
- Implementing Guideline-Recommended Therapy for Patients With CKD: Is Hope on the Horizon?
Published: April 23rd 2015 | Updated:
- The Economics of Renoprotective Therapy in Advanced Diabetic Kidney Disease
Published: February 6th 2015 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Inhaled Insulin Demonstrates Comparable Safety, Lung Function, and Efficacy to Injectable Insulin in Type 1 Diabetes
2
CDC Layoffs Raise Questions About the Future of Public Health Surveillance
3
From $200,000 in Student Loan Debt to Becoming a 7-Figure Pharmacist
4
Mind the Gap: Pharmacy’s Future as AI Evolves in Health Care
5
